Autopsy report · NCT01175967

Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer

“Unable to meet accrual due to changing practice patters”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 4 years 11 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

UNC Lineberger Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer

Interventions

Palliative Performance Scale version 2 (PPSv2); McCorkle Symptom Distress Scale (SDS); Geriatric Assessment; Medical Records Abstraction

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (67% match in meaning)
• Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
  “failure to accrue” (66% match in meaning)
• Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
  “Accrual difficulties” (65% match in meaning)
• Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
  “Accrual was insufficient to meet study endpoints” (64% match in meaning)
• sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
  “Insufficient accrual” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.